Kanuma

— THERAPEUTIC CATEGORIES —
  • Inborn errors of metabolism

Kanuma Generic Name & Formulations

General Description

Sebelipase alfa 20mg/10mL; soln for IV infusion after dilution; preservative-free.

Pharmacological Class

Hydrolytic lysosomal cholesteryl ester and triacylglycerol-specific enzyme.

How Supplied

Single-use vial—1

Generic Availability

NO

Kanuma Indications

Indications

Lysosomal acid lipase (LAL) deficiency.

Kanuma Dosage and Administration

Adults and Children

<1 month: not established. Give as IV infusion over ≥2hrs; consider further prolonging infusion time for doses >1mg/kg or if hypersensitivity reactions occur. May consider a 1hr infusion for the 1mg/kg dose in those who tolerate the infusion. ≥1 month: 1mg/kg once every other week; increase to 3mg/kg once every other week if suboptimal response. Infants with rapidly progressive deficiency within first 6 months of life: initially 1mg/kg once weekly; increase to 3mg/kg once weekly if suboptimal response; may further increase to 5mg/kg once weekly if continued suboptimal response. May pre-treat with antipyretics and/or antihistamines.

Kanuma Contraindications

Not Applicable

Kanuma Boxed Warnings

Not Applicable

Kanuma Warnings/Precautions

Warnings/Precautions

Monitor for hypersensitivity reactions during and after infusion; interrupt or lower infusion rate based on severity. Discontinue immediately and treat if severe hypersensitivity including anaphylaxis occurs. Eggs or egg products allergy. Pregnancy. Nursing mothers.

Kanuma Pharmacokinetics

See Literature

Kanuma Interactions

Not Applicable

Kanuma Adverse Reactions

Adverse Reactions

Diarrhea, vomiting, fever, rhinitis, anemia, cough, nasopharyngitis, urticaria, headache, oropharyngeal pain, asthenia, constipation, nausea.

Kanuma Clinical Trials

See Literature

Kanuma Note

Not Applicable

Kanuma Patient Counseling

See Literature

Images